Amicus Therapeutics (FOLD) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates
May 9, 2017 7:30 AM EDTÂ Â 100+ Fabry Disease Patients Now on Reimbursed Galafold (migalastat) in the EU
On Target to Reach 300 Patients on Galafold by Year-End 2017
Additional Important Phase 1/2 Pompe Clinical Data Expected in 2Q17 and 3Q17
Phase 3 EB Topline Data on Track for 3Q17
CRANBURY, N.J., May 09, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced... More
